Cat. No.: HY-10172

IMD-0354

(Synonyms: IKK2 Inhibitor V)

26 Cited Publications

Avis client

Based on 26 publication(s) in Google Scholar

IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC₅₀ of 1.2 uM.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.26%
CAS No.: 978-62-1
Formule: C₁₅H₈ClF₆NO₂
Masse moléculaire:383.67

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

IMD-0354 Chemical Structure

CAS No.: 978-62-1

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (26)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity^[1]. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC₅₀ of 1.2 uM^[2].

IC₅₀ & Target^[1]^[2]

IKKβ	NF-κB 1.2 μM (IC₅₀)

Voir tous les produits spécifiques à Isoform IKK :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	4.1 μM Compound: 16	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay	[PMID: 32045239]
A549	IC₅₀	1.27 μM Compound: IMD-0354	Inhibition of NFkappaB (unknown origin) expressed in human A549 cells co-transfected with pNFkappaB-Luc vector assessed as reduction in TNFalpha-induced NFkappaB transcriptional activity co-incubated for 7 hrs in presence of TNFalpha by bright-glo lucifer Inhibition of NFkappaB (unknown origin) expressed in human A549 cells co-transfected with pNFkappaB-Luc vector assessed as reduction in TNFalpha-induced NFkappaB transcriptional activity co-incubated for 7 hrs in presence of TNFalpha by bright-glo lucifer	[PMID: 31057738]
HepG2	IC₅₀	10.19 μM Compound: 3d	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 28126437]
HFF	IC₅₀	16 nM Compound: 3j	Antiapicomplexan activity against Toxoplasma gondii RH tachyzoites expressing yellow fluorescent protein infected in HFF cells after 72 hrs by fluorescence assay Antiapicomplexan activity against Toxoplasma gondii RH tachyzoites expressing yellow fluorescent protein infected in HFF cells after 72 hrs by fluorescence assay	[PMID: 22970937]
HL-60	IC₅₀	0.16 μM Compound: 65	Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
Jurkat	IC₅₀	0.48 μM Compound: 65	Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
KG-1	IC₅₀	0.5 μM Compound: 65	Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
Macrophage	IC₅₀	5.2 μM Compound: 1, IMD-0354	Cytotoxicity against mouse macrophage cell line J774.1 (ATCC TIB-67) for 3 days by Alamar Blue Cytotoxicity against mouse macrophage cell line J774.1 (ATCC TIB-67) for 3 days by Alamar Blue	[PMID: 23211970]
MDA-MB-231	IC₅₀	0.64 μM Compound: IMD-0354	Antiproliferative activity against human MDA-MB-231 cells assessed as DNA content after 72 hrs by Hoechst 33258 staining based fluorescence assay Antiproliferative activity against human MDA-MB-231 cells assessed as DNA content after 72 hrs by Hoechst 33258 staining based fluorescence assay	[PMID: 30108896]
MDA-MB-231	IC₅₀	0.85 μM Compound: IMD-0354	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTox green assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTox green assay	[PMID: 30108896]
MG-63	IC₅₀	48.72 μM Compound: IMD-0354	Cytotoxicity against human MG-63 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MG-63 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33530028]
NALM-6	IC₅₀	0.63 μM Compound: 65	Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
Platelet	IC₅₀	0.57 μM Compound: 1; IMD-0354	Antagonist activity P2X1 receptor in Apyrase pre-treated human platelets assessed as inhibition of collagen-induced platelet aggregation pre-incubated for 30 mins before collagen stimulation by aggregometry Antagonist activity P2X1 receptor in Apyrase pre-treated human platelets assessed as inhibition of collagen-induced platelet aggregation pre-incubated for 30 mins before collagen stimulation by aggregometry	[PMID: 32345019]
Platelet	IC₅₀	3.64 μM Compound: 1; IMD-0354	Antagonist activity P2X1 receptor in Apyrase pre-treated human platelets assessed as inhibition of TRAP6-induced platelet aggregation pre-incubated for 30 mins before TRAP6 stimulation by aggregometry Antagonist activity P2X1 receptor in Apyrase pre-treated human platelets assessed as inhibition of TRAP6-induced platelet aggregation pre-incubated for 30 mins before TRAP6 stimulation by aggregometry	[PMID: 32345019]
Platelet	IC₅₀	4.73 μM Compound: 1; IMD-0354	Antagonist activity P2X1 receptor in human platelets assessed as inhibition of ADP-induced platelet aggregation pre-incubated for 30 mins before ADP stimulation by aggregometry Antagonist activity P2X1 receptor in human platelets assessed as inhibition of ADP-induced platelet aggregation pre-incubated for 30 mins before ADP stimulation by aggregometry	[PMID: 32345019]
U2OS	IC₅₀	50.91 μM Compound: IMD-0354	Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33530028]

In Vitro

IMD-0354 inhibits NF-κB activity in HMC-1 cells, resulting in complete repression of growth factor-independent proliferation of mast cells. When the DNA-binding activity of NF-κB is inhibited by treatment with IMD-0354, cell proliferation is completely suppressed. HMC-1 cells are incubated with increasing concentrations of IMD-0354 or STI571 for 24, 48, and 72 hours, and numbers and viability of cells are determined by a dye exclusion test and an MTT assay. IMD-0354 suppresses cell proliferation in a time- and dose-dependent manner. The inhibitory effect of IMD-0354 is remarkable, even at lower concentrations, when compared with that of STI571^[1].
IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC₅₀ of 1.2±0.3 uM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Daily administration with 5 mg/kg IMD-0354 significantly suppresses tumor expansion in nude mice implanted with established MDA-MB-231 tumors. In mice treated with IMD-0354, tumor progression is restrained^[3]. The number of infiltrating cells in aqueous humor is 53.6±9.8×10⁵, 72.5±17.0×10⁵, 127.25±32.0×10⁵, and 132.0±25.0×10⁵ cells/mL in rats treated with 30, 10, 3, or 0 mg/kg of IMD-0354, respectively. The total protein concentrations of aqueous humor are 92.6±3.1 mg/mL, 101.5±6.8 mg/mL, 112.6±1.9 mg/mL, and 117.33±1.8 mg/mL in rats treated with 30, 10, 3, and 0 mg/kg of IMD-0354, respectively^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 978-62-1
Appearance Solid
Masse moléculaire 383.67
Formule C₁₅H₈ClF₆NO₂
Color White to off-white
SMILES

O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC(Cl)=CC=C2O
Synonyms

IKK2 Inhibitor V
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (26)

All Flow CytometryWBIFELISAHistological Imaging/Staining

Sort by:

Journal Impact Factor

Cancer Res

Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities. [Abstract]

2026 Jul 2;86(13):3270-3286. PMID: 42008116
Cell Rep Med

HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion. [Abstract]

2026 Apr 21;7(4):102691. PMID: 41861828
Sci Adv

Deficient chaperone-mediated autophagy facilitates LPS-induced microglial activation via regulation of the p300/NF-κB/NLRP3 pathway. [Abstract]

2023 Oct 6;9(40):eadi8343. PMID: 37801503

IMD-0354 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Oct 6;9(40):eadi8343. [Abstract]

IMD-0354 (1.5 μM; 12 h) reversed the increases in the production of the inflammatory factor iNOS in BV2 cells induced by LAMP2A deficiency.
Mol Biomed

Deleting fibroblast growth factor 2 in macrophages aggravates septic acute lung injury by increasing M1 polarization and inflammatory cytokine secretion. [Abstract]

2024 Oct 22;5(1):50. PMID: 39436561

IMD-0354 purchased from MedChemExpress. Usage Cited in: Mol Biomed. 2024 Oct 22;5(1):50. [Abstract]

IMD-0354 (1.2 µM; 3 h) caused a noticeable decrease in the percentage of iNOS in FGF2 KO BMDM.
Pharmacol Res

RNA-binding motif 4 promotes angiogenesis in HCC by selectively activating VEGF-A expression. [Abstract]

2023 Jan:187:106593. PMID: 36496136
Cell Death Dis

Inhibition of miR-450b-5p ameliorates hepatic ischemia/reperfusion injury via targeting CRYAB. [Abstract]

2020 Jun 12;11(6):455. PMID: 32532961

IMD-0354 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Jun 12;11(6):455. [Abstract]

IMD-0354 (10 μM; 24 h) reversed activation of IKKβ derived from CRYAB blockade in RAW 264.7 cells.

IMD-0354 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Jun 12;11(6):455. [Abstract]

IMD-0354 (10 μM; 24 h) moderated the release of IL-1β, IL-6, and TNF-α in RAW 264.7 cells induced by CRYAB shortage to some extent.

IMD-0354 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Jun 12;11(6):455. [Abstract]

IMD-0354 (5 mg/kg; 24 h) partially reversed the hepatic pathological lesion induced by CRYAB repression in hepatic IRI (ischemia/reperfusion injury) mice.
Cancer Lett

Intratumoral injection of mRNA encoding survivin in combination with STAT3 inhibitor stattic enhances antitumor effects. [Abstract]

2024 Jul 5:217111. PMID: 38972347
Acta Pharmacol Sin

ATM promotes bone metastatic propensity of breast cancer by inducing osteoclastogenesis via the NFκB-CCL2 pathway. [Abstract]

2025 Dec 1. PMID: 41326811
Dev Cell

MITA/STING-driven CD38 induction in Siglec-Flow macrophages promotes regulatory T cell survival and non-small cell lung cancer progression. [Abstract]

2026 Jan 12:S1534-5807(25)00768-3. PMID: 41529690
Cancer Immunol Res

High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects. [Abstract]

2023 Jul 5;11(7):895-908. PMID: 37062030
Clin Sci

High sodium promotes the secretion and synthesis of PTH through PiT-1-IKKβ pathway in parathyroid gland in vitro. [Abstract]

2023 Jun 28;137(12):947-962. PMID: 37337945
Mol Ther Nucleic Acids

Upregulation of miR-520c-3p via hepatitis B virus drives hepatocellular migration and invasion by the PTEN/AKT/NF-κB axis. [Abstract]

2022 May 20:29:47-63. PMID: 35795482
Inflamm Res

Fibroblast growth factor receptor 4 deficiency in macrophages aggravates experimental colitis by promoting M1-polarization. [Abstract]

2024 Sep;73(9):1493-1510. PMID: 38981913
Front Cell Dev Biol

Tumor-Derived Extracellular Vesicles Promote Activation of Carcinoma-Associated Fibroblasts and Facilitate Invasion and Metastasis of Ovarian Cancer by Carrying miR-630. [Abstract]

2021 Jun 30:9:652322. PMID: 34277601
Biochim Biophys Acta Mol Basis Dis

Directed elimination of senescent cells attenuates development of osteoarthritis by inhibition of c-IAP and XIAP. [Abstract]

2019 Jun 26;1865(10):2618-2632. PMID: 31251987
iScience

Protective effect of Zymosan-A against radiation-induced premature ovarian insufficiency in a murine model. [Abstract]

2026 Feb 14;29(4):115027. PMID: 41858627
iScience

Possible involvement of a MEG3-miR-21-SPRY1-NF-κB feedback loop in spermatogenic cells proliferation, autophagy, and apoptosis. [Abstract]

2024 Sep 10;27(10):110904. PMID: 39398251
Carcinogenesis

Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer. [Abstract]

2020 Nov 13;41(11):1529-1542. PMID: 32603404
Mol Immunol

FAM49B, restrained by miR-22, relieved hepatic ischemia/reperfusion injury by inhibiting TRAF6/IKK signaling pathway in a Rac1-dependent manner. [Abstract]

2022 Mar:143:135-146. PMID: 35131594
Cytokine

Inhibition of macrophage migration inhibitory factor alleviates LPS-induced inflammation response of HEI-OC1 cells via suppressing NF-κB signaling. [Abstract]

2022 Feb:150:155776. PMID: 34864396
Mol Cell Endocrinol

In vitro primary hyperparathyroidism model application of computationally repurposed drugs. [Abstract]

2024 Apr 1:583:112159. PMID: 38228226
Am J Reprod Immunol

Inhibition of TLR2/TLR4 alleviates the Neisseria gonorrhoeae infection damage in human endometrial epithelial cells via Nrf2 and NF-Kβsignaling. [Abstract]

2020 Nov;142:103192. PMID: 32950783
Oncol Lett

2025 Dec 18.
Anticancer Drugs

AZD7762 induces CRBN dependent BAG3 degradation through ubiquitin-proteasome pathway. [Abstract]

2024 Jan 1;35(1):46-54. PMID: 37449977
Vascular

Nuclear factor-kappa B activation inhibits proliferation and promotes apoptosis of vascular smooth muscle cells. [Abstract]

2018 Dec;26(6):634-640. PMID: 30003828
Res Sq

2026 Jan 9.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (260.64 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6064 mL

13.0320 mL

26.0641 mL

5 mM

0.5213 mL

2.6064 mL

5.2128 mL

10 mM

0.2606 mL

1.3032 mL

2.6064 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.52 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[1]

HMC-1 cells (2×10⁵ cells/mL) are incubated with various concentrations of IMD-0354 (0.1, 0.5, 1, 5 and 10 uM), STI571, or pyrrolidine dithiocarbamate (PDTC) for the indicated hours, and viable cell numbers are calculated with the use of the trypan blue dye exclusion test at each time point. Cells (2×10⁵ cells/mL) are incubated in phenol red free α-MEM containing 10% FCS (for HMC-1 and IC-2 cells) or 5% FCS (for CBhCMCs), and antibiotics with or without various concentrations of IMD-0354 (0.1, 0.5, 1, 5 and 10 uM), STI571, or PDTC. IC-2^WT cells and CBhCMCs are incubated in the presence of 100 ng/mL recombinant rat or recombinant human SCF. One hundred microliters of cell suspension is applied to each well of 96-well culture plates and are incubated for 24, 48, and 72 hours. Before 4 hours from the end of the culture, 10 μL of 5 mg/mL MTT dissolved in PBS is added to each well. The reaction is stopped with the addition of 100 μLof 10% SDS in 0.01 N HCl. Absorbance is measured at 577 nm with ImmunoMini NJ-2300^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]^[4]

Mice^[3]
MDA-MB-231 cells are suspended in PBS (5×10⁶ cells/100 μL mouse) and s.c. injected to the back of female BALB/c nude mice at the age of 4 to 5 weeks. After growth, the tumor is removed surgically and 100 mg of each established tumor is transplanted to the back of other female nude mice at the age of 4 weeks under ether anesthesia. IMD-0354 is suspended in saline and 5 mg/kg body weight IMD-0354 (suspended in 100 μL/mouse) is given to each mouse by i.p. injection once a day for 28 days after the implantation. Saline is injected in nude mice as a control. Estimated tumor volume (mm3) and tumor weight (mg) are calculated.
Rats^[4]
Eight-week-old male Lewis rats (180-220 g) are used. Endotoxin-induced uveitis (EIU) is induced with subcutaneous injection with 200 μg LPS from Escherichia coli that has been diluted in 200 μL PBS. At the same time, the rats are injected intraperitoneally with 30, 10, or 3 mg/kg of IMD-0354, diluted in 500 μL of 0.5% CMC. Control EIU rats are intraperitoneally administered 500 μL of CMC alone. Naïve rats are used as controls. All experiments are performed in triplicate with five animals in each group.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (286 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Tanaka A, et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood. 2005 Mar 15;105(6):2324-31. [Content Brief]

[2]. Li YR, et al. Study of the inhibitory effects on TNF-α-induced NF-κB activation of IMD0354 analogs. Chem Biol Drug Des. 2017 Dec;90(6):1307-1311. [Content Brief]

[3]. Tanaka A, et al. A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 2006 Jan 1;66(1):419-26. [Content Brief]

[4]. Lennikov A, et al. Amelioration of endotoxin-induced uveitis treated with an IκB kinase β inhibitor in rats. Mol Vis. 2012;18:2586-97. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6064 mL	13.0320 mL	26.0641 mL	65.1602 mL
	5 mM	0.5213 mL	2.6064 mL	5.2128 mL	13.0320 mL
	10 mM	0.2606 mL	1.3032 mL	2.6064 mL	6.5160 mL
	15 mM	0.1738 mL	0.8688 mL	1.7376 mL	4.3440 mL
	20 mM	0.1303 mL	0.6516 mL	1.3032 mL	3.2580 mL
	25 mM	0.1043 mL	0.5213 mL	1.0426 mL	2.6064 mL
	30 mM	0.0869 mL	0.4344 mL	0.8688 mL	2.1720 mL
	40 mM	0.0652 mL	0.3258 mL	0.6516 mL	1.6290 mL
	50 mM	0.0521 mL	0.2606 mL	0.5213 mL	1.3032 mL
	60 mM	0.0434 mL	0.2172 mL	0.4344 mL	1.0860 mL
	80 mM	0.0326 mL	0.1629 mL	0.3258 mL	0.8145 mL
	100 mM	0.0261 mL	0.1303 mL	0.2606 mL	0.6516 mL

Keywords

IMD-0354

26 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

IMD-0354

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) IMD-0354

Voir tous les produits spécifiques à Isoform IKK

Activité biologique

Chemical Information

Publications (26)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

IMD-0354

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) IMD-0354

Voir tous les produits spécifiques à Isoform IKK

Activité biologique

Chemical Information

Publications (26)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

IMD-0354 Related Classifications

HY-10172 Related Classifications